Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy

Sponsor
Federico II University
Study ID
NCT07375225
Status
Recruiting
Apply to this trial

Conditions

  • Hypercholesterolaemia

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.

Key Dates

First listed
Jan 29, 2026
Start date
Dec 1, 2024
Status verified
Jan 2026
Primary completion
Dec 1, 2026
Completion
Dec 1, 2027

Study Design

Enrollment
1,500 participants (estimated)

Arms

  • Arm: Subjects with hyperlipidaemia under Alirocumab 300 mg treatment.
    Subjects with hyperlipidaemia

Primary Outcome Measure

Description of adherence of treatment with alirocumab 300mg in a real-life Italian population. [ Time Frame: 6-12-24-36 months ]

Central Contacts

Related Studies